Latest T cells Stories

Better understanding of cells' development has implications in study of inflammatory diseases Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells (ILCs). Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body's...

St. Jude Children's Research Hospital advances understanding of how T cells craft an appropriate immune response; setting the stage for new strategies to intervene if the system goes awry A properly functioning immune system is a lesson in balance, providing protection against disease without attacking healthy tissue. Work led by St. Jude Children's Research Hospital scientists and published recently in Nature Immunology has identified a mechanism that helps T cells find that sweet spot...

Compounds enhance immune function in mammals SANTA ROSA, Calif., April 30, 2013 /PRNewswire/ -- The United States Patent and Trademark Office has awarded Isaac Eliaz, M.D., patent # 8,426,567, on April 23, 2013 for modified citrus pectin (MCP) and modified alginates as: "A method for enhancing mammalian immunological function." Specifically, the patent recognizes that MCP and modified alginate help improve the immune response in mammals, particularly humans. "I am very excited that...

The tiny thymus teaches the immune system to ignore the teeming, foreign bacteria in the gut that helps you digest and absorb food, researchers say. When immune cells recognize essential gut bacteria as foreign, inflammatory bowel disease such as ulcerative colitis and Crohn's disease can be the painful, debilitating result. In a study published in the journal Nature, researchers show that the regulatory T cells, or Tregs, that keep this from happening in most of us come from the tiny...

The findings suggest a new approach to clearing infections from AIDS to hepatitis Scientists at The Scripps Research Institute (TSRI) have made a counterintuitive finding that may lead to new ways to clear persistent infection that is the hallmark of such diseases as AIDS, hepatitis B and hepatitis C. The study, reported in the April 12, 2013 issue of the journal Science, focused on the activity of the body's type 1 interferon (IFN-I) proteins. Since its discovery over 50 years ago,...

Brett Smith for redOrbit.com - Your Universe Online Job training can allow workers to take on new responsibilities and a team of oncologists from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York found that the same thing applies to the body’s immune system. By essentially taking T cells, a type of white blood cell, back to school – the oncologists were able to successfully eradicate a certain type of acute leukemia. Similar previous research has shown promise in young...

MEMPHIS, Tenn., March 19, 2013 /PRNewswire-USNewswire/ -- The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for St. Jude's invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults. "This groundbreaking invention enables human immune cells to recognize and attack certain cells that cause leukemia and lymphoma,...

Alan McStravick for redOrbit.com - Your Universe Online Over the previous several years, medical professionals have noted and documented marked increases in the prevalence of autoimmune diseases. An international team of scientists and researchers have come together in an attempt to identify the cause behind the increase in diseases like multiple sclerosis, rheumatoid arthritis, psoriasis and other diseases. What they have learned is that there is a connection between dietary salt intake...

TORONTO, Feb. 12, 2013 /PRNewswire/ - SCiAN Services, Inc., a North American Clinical Data Management - Biostatistics CRO and EDC solution provider announces that Adaptimmune has selected SCiAN's EDC(PRO) platform to manage its clinical trials starting in 2013.  Following a review of several EDC vendors and CROs a services agreement was executed with SCiAN to deliver a comprehensive systems and services solution for Web-based data capture and data management, including...

MUMBAI, India, February 4, 2013 /PRNewswire/ -- - GBR 830 is the first antagonistic antibody targeting OX40 and is a potential Global First-in-class molecule - OX40, also known as CD134, plays a key role in T-cell mediated autoimmune disorders. Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel...